In vivo leukocyte labeling with intravenous ferumoxides/protamine sulfate complex and in vitro characterization for cellular magnetic resonance imaging.
Cellular labeling with ferumoxides (Feridex IV) superparamagnetic iron oxide nanoparticles can be used to monitor cells in vivo by MRI. The objective of this study was to use histology and MRI to evaluate an in vivo, as opposed to in vitro, technique for labeling of mononuclear leukocytes as a means of tracking inflammatory processes in the brain. Long-Evans rats were intravenously injected with 20 mg/kg ferumoxides, ferumoxtran-10, or ferumoxytol with or without protamine sulfate. Leukocytes and splenocytes were evaluated by cell sorting and iron histochemistry or were implanted into the brain for MRI. Injection of ferumoxides/protamine sulfate complex IV resulted in iron labeling of leukocytes (ranging from 7.4 +/- 0.5% to 12.5 +/- 0.9% with average 9.2 +/- 0.8%) compared with ferumoxides (ranging from 3.9 +/- 0.4% to 6.3 +/- 0.5% with average 5.0 +/- 0.5%) or protamine sulfate alone (ranging from 0% to 0.9 +/- 0.7% with average 0.3 +/- 0.3%). Cell sorting analysis indicated that iron-labeled cells were enriched for cell types positive for the myelomonocytic marker (CD11b/c) and the B lymphocyte marker (CD45RA) and depleted in the T cell marker (CD3). Neither ferumoxtran-10 nor ferumoxytol with protamine sulfate labeled leukocytes. In vivo ferumoxides/protamine sulfate-loaded leukocytes and splenocytes were detected by MRI after intracerebral injection. Ferumoxides/protamine complex labeled CD45RA-positive and CD11b/c-positive leukocytes in vivo without immediate toxicity. The dose of feumoxides in this report is much higher than the approved human dose, so additional animal studies are required before this approach could be translated to the clinic. These results might provide useful information for monitoring leukocyte trafficking into the brain.
Wu
Y Jeffrey
YJ
Research Service, Veterans Administration Medical Center, Oregon Health and Sciences University, Portland, Oregon 97239, USA.
Muldoon
Leslie L
LL
Varallyay
Csanad
C
Markwardt
Sheila
S
Jones
Richard E
RE
Neuwelt
Edward A
EA
D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D001921:Brain / Q000166:cytology / Q000378:metabolism / Q000601:surgery; D002465:Cell Movement; D003287:Contrast Media / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D003911:Dextrans; D005260:Female; D052203:Ferrosoferric Oxide / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D005434:Flow Cytometry; D016130:Immunophenotyping; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000637:transplantation; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles; D010087:Oxides / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D011479:Protamines / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D051381:Rats; D020318:Rats, Long-Evans; D013194:Staining and Labeling / Q000379:methods*; D013997:Time Factors; D014018:Tissue Distribution
D015703:Antigens, CD; D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D011479:Protamines; C097921:ferumoxtran-10; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide